Author(s): Plosker G, Faulds D
Troglitazone is the first of a new group of oral antidiabetic drugs, the thiazolidinediones, and is indicated for the treatment of patients with type 2 (non-insulin-dependent) diabetes mellitus. Troglitazone acts by enhancing the effects of insulin at peripheral target sites and, unlike the sulphonylurea drugs, is not associated with hypoglycaemia when administered as monotherapy. Clinical trials with troglitazone (usually 200 to 600 mg/day) in patients with type 2 diabetes mellitus consistently showed marked improvement in glycaemic control, as well as reductions in fasting serum insulin, C-peptide and triglyceride levels. Comparative studies with either glibenclamide (glyburide) or metformin indicated similar glycaemic control with troglitazone or these agents. Serum insulin levels were lower with troglitazone than with glibenclamide. Clinical trials of up to approximately 2 years' duration showed that glycaemic control is maintained with troglitazone on a long term basis. In general, troglitazone is well tolerated by the majority of patients. However, discontinuation of troglitazone because of elevated liver enzyme levels occurs in approximately 2% of patients receiving the drug, and frequent monitoring of liver enzymes is required (e.g. at least 11 times during the first year of therapy). Among patients who started troglitazone therapy in 1998 (after the incorporation of a boxed warning and increased monitoring requirements in the product labelling), the estimated risk of liver-related death is approximately 1 in 100,000.
Conclusions: Troglitazone improves the ability of target cells to respond to insulin. The drug has been shown to improve glycaemic control in patients with type 2 diabetes mellitus when used as monotherapy or in combination with other oral antidiabetic drugs or insulin, and its efficacy is similar to that of glibenclamide or metformin. Although troglitazone is generally well tolerated, close monitoring of liver enzyme function is required to minimise the rare occurrence of serious hepatic dysfunction. Drug acquisition and liver function monitoring costs, as well as potential adverse effects, are important factors that may ultimately determine the precise place of troglitazone in the management of type 2 diabetes mellitus. Nevertheless, as the first member of a new class of oral antidiabetic agents, the thiazolidinediones, troglitazone offers an effective treatment option in patients with type 2 diabetes mellitus through its action of improving insulin sensitivity.
Referred From: https://www.ncbi.nlm.nih.gov/pubmed/10193691
Author(s): Ponte C
Author(s): Mensing C, Boucher J, Cypress M, Weinger K, Mulcaby K, et al.
Author(s): Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, et al.
Author(s): Foreyt JP, Poston WS 2nd
Author(s): Baliga BS, Fonseca VA (l997) Recent advances in the treatment of type II diabetes mellitus
Author(s): Bailey CJ, Turner RC
Author(s): Mann JF
Author(s): Stang M, Wysowski DK, Butler-Jones D
Author(s): Whittemore R
Author(s): Wing RR, Anglin K
Author(s): DeFronzo RA
Author(s): Wen LK, Shepherd MD, Parchaman ML
Author(s): Savoca MR, Miller CK, Quandt SA
Author(s): Turner R, Cull C, Holman R
Author(s): Arc A, Korhonen T, Halinen M
Author(s): Somogyi A, Stockley C, Keal J, Rolan P, Bockner F (1 987) Reduction of metformin renal tubular secretion by cimetidine in man
Author(s): Lubbos H, Miller JL, Rose LI
Author(s): Yeap BB
Author(s): Kubacka RT, Antal EJ, Juhi RP, Weishman IR (1 996) Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects
Author(s): Christensen LK, Hansen J, Kristensen M
Author(s): Kivisto KT, Neuvonen PJ
Author(s): Ben-Ami H, Nagachandran P, Mendelson A, Edoute Y
Author(s): Nelson KM, Reiber G, Boyko EJ, Nhanes III
Author(s): Huang CL, Wu SC, Jeng CY, Lin LC
Author(s): Hurley CC, Shea CA
Author(s): Aljasem LI, Peyrot M, Wissow L, Rubin RR
Author(s): Diabetes Control and Complications Trial Research Group
Author(s): Ohkubo Y, Kishikawa H, Araki E, Myata T, Isami S, et al.
Author(s): Swift CS, Armstrong JE, Berman KA, Cambell RK, Pond-Smith D
Author(s): Polit DF, Hungler BP
Author(s): Gerich JE, Odawara M, Terauchi Y
Author(s): Bergenstal RM, Gavin JR, Global Consensus conference on Glucose monitoring panel
Author(s): Renard E
Author(s): Tan MY, Magarey J
Author(s): Mastura I, Mimi O, Piterman L, Teng CL, Wijesinha S
Author(s): Ismail IS, Nazaimoon W, Mohamad W, Letchuman R, Hew FL, et al.
Author(s): Pahor M, Psaty BM, Alderman MH, Applegate WB, Williamson JD, et al.
Author(s): Samuel-Hodge CD, Fernandez LM, Henrfquez-Roldan CF, Johnston LF, Keyserling TC
Author(s): Subar AF, Kipnis V, Troiano RP, Midthune D, Schoeller DA, et al.
Author(s): Boehm S, Schlenk EA, Funnell MM, Powers H, Ronis DL
Author(s): Travis T
Author(s): Wen LK, Parchman ML, Shepherd MD
Author(s): Bantle JP, Wylie-Rosett J, Albright AL, Apovian CM, Clark NG, et al.
Author(s): Nutrition sub-committee of the diabetes Care Advisory Committee of Diabetes UK
Author(s): Stein CJ, Colditz GA
Author(s): Hadaegh F, Ghasemi A, Padyab M, Tohidi M, Azizi F
Author(s): Dalgård C, Thurøe A, Haastrup B, Haghfelt T, Stender S
Author(s): Christian JG, Bessesen DH, Byers TE, Christian KK, Goldstein MG, et al.
Author(s): Heshka S, Greenway F, Anderson JW, Atkinson RL, Hill JO, et al.
Author(s): Farmer J
Author(s): Cefalu WT
Author(s): Caldwell MA, Peters Kj, Dracup KA
Author(s): Vincent D, Pasvogel A, Barrera L
Author(s): Tan SL, Yong LS, Wan S, Wong ML
Author(s): Hawthone K
Author(s): Middlekoop B, van der Wal G
Author(s): Kulzer B, Hermanns n, Reinecker H, Haak T
Author(s): Clark M, Hampson SE, Avery L, Simpson R
Author(s): Brown S
Author(s): Deakin T, Cade J, Williams R, Greenwood D
Author(s): Raji A, Gomes H, Beard JO, MacDonald P, Conlin PR
Author(s): Clement S
Author(s): Elasy T, Ellis S, Brown A, Pichert J
Author(s): Rubin RR
Author(s): Evans J, Newton R, Ruta D, MacDonald T, Stevenson R, et al.
Author(s): Rhee MK, Slocum W, Ziemer DC, Culler SD, Cook CB, et al.
Author(s): Murata G, Shah J, Duckworth W, Wendel C, Mohler M, et al.
Author(s): Krass I, Armour CL, Mitchell B, Brilliant M, Dienaar R, et al.
Author(s): Suppapitiporn S, Chindavijak B, Onsanit S
Author(s): Welschen LM, Bloemendal E, Nijpels G, Dekker J, Heine RJ, et al.
Author(s): Arcury TA, Preisser JS, Gesler WM, Powers JM
Author(s): Strauss K, MacLean C, Troy A, Littenberg B
Author(s): Westaway MS, Seager JR, Rheeder P, Van Zyl DG
Author(s): Khoo KL, Liew YM, Tan H, Sambhi JS, Hatijah BA
Author(s): Leong KC, Chen WS, Leong KW, Mastura I, Mimi O, et al.